Long non-coding RNAs as epigenetic mediator and predictor of glioma progression, invasiveness, and prognosis

Semin Cancer Biol. 2022 Aug:83:536-542. doi: 10.1016/j.semcancer.2020.08.016. Epub 2020 Sep 10.

Abstract

Gliomas are aggressive brain tumors with high mortality rate. Over the past several years, non-coding RNAs, specifically the long non-coding RNAs (lncRNAs), have emerged as biomarkers of considerable interest. Emerging data reveals distinct patterns of expressions of several lncRNAs in the glioma tissues, relative to their expression in normal brains. This has led to the speculation for putative exploitation of lncRNAs as diagnostic biomarkers as well as biomarkers for targeted therapy. With a focus on lncRNAs that have shown promise as epigenetic biomarkers in the proliferation, migration, invasion, angiogenesis and metastasis in various glioma models, we discuss several such lncRNAs. The data from cell line / animal model-based studies as well as analysis from human patient samples is presented for the most up-to-date information on the topic. Overall, the information provided herein makes a compelling case for further evaluation of lncRNAs in clinical settings.

Keywords: Epigenetic; Glioma; MALAT1; Non-coding RNA; lncRNAs.

Publication types

  • Review

MeSH terms

  • Animals
  • Biomarkers
  • Epigenesis, Genetic
  • Gene Expression Regulation, Neoplastic
  • Glioma* / diagnosis
  • Glioma* / genetics
  • Glioma* / metabolism
  • Humans
  • Prognosis
  • RNA, Long Noncoding* / genetics

Substances

  • Biomarkers
  • RNA, Long Noncoding